Medtronic delivered its most robust full-year revenue expansion in ten years, fueled by accelerating demand for its cardiac device portfolio. Fourth-quarter revenue of $9.81 billion exceeded the Street’s $9.63 billion forecast, while adjusted earnings per share of $1.55 narrowly topped the $1.54 consensus figure. The medical device giant’s full-year organic revenue expansion of 5.8% represented its strongest annual showing in a decade.
While the top-line figures impressed, certain underlying details raised eyebrows — particularly the fiscal 2027 EPS guidance band of $5.90 to $6.00, which trailed the $6.06 that Wall Street had anticipated.
Tariff-related expenses represent a tangible challenge. Management anticipates approximately $300 million in tariff-related headwinds during fiscal 2027, a notable increase from the roughly $185 million absorbed in fiscal 2026. Leadership has been transparent about acknowledging this cost pressure.
The cardiovascular division served as the primary growth catalyst for the quarter. Sales climbed 13.8% to $3.8 billion — representing nearly 40% of total corporate revenue. Cardiac Ablation Solutions exploded higher by 78% globally, including exceptional 124% growth domestically, capturing an additional 8 percentage points of market share.
Pulsed field ablation technology and transcatheter aortic valve replacement procedures represent the two therapeutic areas experiencing the steepest adoption trajectories currently, and Medtronic has established substantial traction in both categories.
The Micra leadless pacemaker platform delivered mid-teens percentage growth, while the OmniaSecure defibrillation lead experienced a successful domestic commercial introduction.
Neuroscience division revenue increased 5% to $2.75 billion, falling marginally below the $2.76 billion analyst projection. Medical Surgical segment sales registered $2.39 billion, climbing 8% on a reported basis and 5.1% organically, with Acute Care & Monitoring achieving low double-digit percentage gains.
Diabetes segment revenue advanced 15% on a reported basis to $837 million, and this business unit will remain within Medtronic‘s structure throughout the entire 12-month fiscal 2027 guidance period.
Medtronic has pursued an aggressive tuck-in acquisition strategy following the separation of its diabetes division. Throughout the quarter and full fiscal year, the company finalized the CathWorks transaction, disclosed intentions to acquire Scientia Vascular and SPR Therapeutics (for approximately $650 million combined), and submitted regulatory filings with the FDA seeking clearance for its Hugo robotic-assisted surgical platform for general surgery and gynecologic procedures.
The Hugo regulatory submission marks a significant milestone in the company’s surgical robotics strategy — a competitive arena where Medtronic has been methodically building capabilities.
The company also elevated its quarterly dividend payment to $0.72 per share, extending its dividend growth streak to 49 consecutive years.
Looking ahead to fiscal 2027, Medtronic projects organic revenue growth in the range of 6.75% to 7.25%. Full-year fiscal 2026 revenue totaled $36.4 billion on an 8.4% reported basis and 5.8% organic growth foundation.
The post Medtronic (MDT) Stock Surges on Q4 Beat Despite Tariff Headwinds and Weak FY27 Outlook appeared first on Blockonomi.
